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INTRODUCTION 
 A hemangioma is an abnormal proliferation of blood vessels that 
may occur in any vascularized tissue. Considerable debate exists as to 
whether these lesions are neoplasms, hamartomas, or vascular 
malformations. Mulliken strongly supports classification of hemangiomas 
as neoplasms1, whereas Godanich and Capanacci2 seem to favor a 
hamartomatous classification. There seems to be consensus that the term 
"hemangioma" should refer to "hemangiomas of infancy," which have a 
predictable natural history that includes absence at birth followed by a 
period of growth over 6-18 months and then a period of involution that 
may take several years3.  
 Vascular malformations have been recognized throughout history 
as birthmarks. The cause was thought to be maternal cravings for fruit or 
maternal dreams, moods, and fantasies. Although Blondel disproved 
these theories in 1727, some persist today. In 1866, Dugas conducted a 
scientific analysis of birthmarks and concluded that they were caused by 
defects in embryonic development. Virchow and Wagner established the 
first classification system of vascular malformations, based on channel 
architecture and histomorphologic appearance. 
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REVIEW OF LITERATURE    
 In 19821, Mulliken and Glowacki proposed a classification system 
for vascular birthmarks that correlated natural history and physical 
examination with clinical features; which were subsequently accepted by 
the International Society of Vascular Anomalies in 19964. On the basis of 
cellular kinetics and clinical behavior, there are two major categories of 
vascular anomalies:    
1. Tumors                – lesions that arise by endothelial hyperplasia  
2. Malformations     – lesions that arise by dysmorphogenesis and exhibit 
normal endothelial turnover. 
Tumors Malformations 
Infantile hemangioma Capillary 
Congenital hemangioma Venous 
Verrucous hemangioma Arterial (AVM, AVF, Ectasia, 
aneurysm) 
Hemangioendothelioma Lymphatic 
Miliary hemangiomatosis of infancy Mixed 
Tufted angioma, Glomangioma  
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 Tumors Malformations 
Present at birth Usually postnatal, 
rarely fully grown at 
birth 
Usually at birth 
Male: female ratio 1:3-1:5 1:1 
Incidence 1-2.6% at birth, 10-
12% at 1 year 
0.3-0.5%(portwine 
stain) 
Natural history Phases: proliferating, 
involuting, and 
involuted 
Proportionate growth 
can expand 
Cellular Endothelial 
hyperplasia 
Normal endothelial 
turnover 
Skeletal changes Occasional mass effect 
on adjacent bone; rare 
hypertrophy 
Slow flow: distortion,  
hypertrophy, or 
hypoplasia 
Fast flow: destruction, 
distortion, or 
hypertrophy 
Modified from Mulliken and Young5  
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VASCULAR TUMORS 
INFANTILE HEMANGIOMA       
DEFINITION:          
 It is a benign vascular tumor that appear during first months of life, 
and which characteristically have an initial proliferative phase, followed 
by involuting phase and ending with an involuted phase6. 
ETIOPATHOGENESIS: 
 Hemangiomas are benign tumors that exhibit an early and rapid 
proliferative phase during the first year of life characterized by 
endothelial and pericytic hyperplasia, followed by a slower but steady 
involution phase that may last for years. Neither the cause nor the cell of 
origin of infantile hemangiomas has been elucidated. Theories abound 
and several lines of evidence support several divergent theories of the cell 
of origin, including placental tissue, endothelial progenitor cells, and 
mesenchymal stem cells.  
 Cheung and colleagues7 compared the concordance of hemangioma 
in monozygotic versus dizygotic twins and found no evidence of a strong 
predisposing inherited component. However, Blei and colleagues 
described six rare families segregating hemangiomas and/or vascular 
malformations as an autosomal dominant trait with incomplete 
penetrance8.  This suggested a predisposing mutation in these families 
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segregating the trait. Genetic involvement was bolstered with the genetic 
mapping of a locus on chromosome 5q for hemangioma/malformation 
development in these particular families9, but the gene responsible has yet 
to be identified.  
 Boye and colleagues10showed that endothelial cells derived from 
hemangioma are clonal in origin and demonstrating that they arise from a 
common precursor cell. Mesenchymal stem cells may also play a role in 
the formation of infantile hemangiomas. These cells have been identified 
in hemangioma tissue. Mesenchymal stem cells retain the capacity to 
differentiate into numerous mesodermal cells, including adipocytes, 
suggesting that these cells may be the source of the resultant adipose 
tissue found in involuted hemangiomas11. 
 It has also been suggested that there may be analogies with 
retrolental fibrovascular proliferation seen in premature infants given 
oxygen therapy, and this concept receives an indirect support from the 
higher incidence of infantile hemangiomas in infants born prematurely12. 
An imbalance has been demonstrated between expression of angiogenic 
and anti-angiogenic factors within infantile hemangiomas and adjacent 
normal tissue. Endogenous steroid hormones also play a role in the 
growth of infantile hemangiomas. Both increased serum levels of 17 
βestradiol and increased number of tissue receptors for this hormone in 
the proliferating infantile hemangioma has been demonstrated13.  
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 An alternative interpretation of the present data comes from work 
of North and colleagues, who have documented the expression of 
placental vascular epitopes in hemangiomas. Hemangiomas display high 
levels of immunostaining for the GLUT1 glucose transporter 14, a surface 
protein that is highly expressed in most of the embryonic and fetal 
endothelial cells but is lost in most tissues except at the blood-tissue 
barriers, including microvessels in the central nervous system and the 
placenta. North et al. have expanded on this initial finding to show that 
other antigens associated with placental vessels, including FcγRII, Lewis 
Y antigen, and merosin, are also expressed in hemangioma15. 
 The similarities in gene expression between hemangioma and 
placental vessels might be explained by a somatic mutation in a 
regulatory gene that directs hemangiomal endothelial cells toward a 
placental phenotype, but North and colleagues also suggest an alternative 
theory.  Embolic placental endothelial cells could reach fetal tissues from 
chorionic villi through right-to-left shunts characteristic of the normal 
fetal circulation. If the embolus contained a single endothelial cell or only 
a small number of endothelial cells, this would also be compatible with 
the clonality results obtained by Boye and colleagues10. The fact that 
chorionic villus sampling increases the risk of hemangiomas further 
supports this model, since the local placental injury caused in this 
procedure might increase the shedding of endothelial cells from chorionic 
villi into the fetal circulation16,17. 
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 The placenta and hemangioma share a similar life cycle of robust 
vascular growth. The placenta produces very high levels of the 
proangiogenic cytokine, vascular endothelial growth factor (VEGF). As a 
protective mechanism against uncontrolled angiogenesis in the fetus and 
mother, a soluble form of the VEGF receptor, sFlt-1, found in both 
amniotic fluid and maternal serum, is also produced by the placenta. sFlt-
1 binds circulating VEGF, preventing excessive angiogenesis in 
nonplacental tissues. During postpartum, the connection to the placenta 
and sFlt-1 is removed, abrogating this negative feedback and allowing 
proliferation of cells, such as those in hemangiomas, responsive to 
VEGF18,19. 
 Several VEGF receptors (VEGFRs) may play a role in the 
development of hemangiomas. VEGFR1 on endothelial cells acts as 
a decoy receptor such that the binding of VEGF to this receptor does not 
effect a change in the endothelial cell. However, the binding of VEGF to 
VEGFR2 elicits endothelial cell proliferation and migration. 
Hemangioma endothelial cells exhibit low levels of VEGFR1, with 
marked constitutive activation of VEGFR2. Gene transcription for 
VEGFR1 in hemangioma cells is dependent on nuclear factor of activated 
T cells (NFAT). This, in turn, is dependent on a pathway involving beta1 
integrin, VEGFR2, and integrin like receptor tumor endothelial marker-8. 
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 Missense mutations in genes encoding for VEGFR2 and tumor 
endothelial marker-8 have been identified in a subset of infantile 
hemangiomas. These mutations are likely to be responsible for the 
constitutive activation of VEGFR2 and resultant endothelial cell 
proliferation. Soluble VEGFR1 or anti-VEGF antibodies normalize the 
constitutive VEGFR2 signaling20.    
PATHOLOGY:                          
Proliferative phase:         
 In the earliest phase of growth of infantile hemangiomas, there is a 
solid mass of proliferating endothelial cells, with few if any lumina. Later 
in the proliferative phase, capillary sized lumina are apparent, lined by 
plump endothelial cells. Endothelial cells express phenotypic markers of 
maturity such as CD 31, factor VIII related antigen (von willebrand 
factor). Reticulin staining confirms that each group of endothelial cell is 
surrounded by a limiting membrane of reticulin fibres. PAS staining 
shows thickened basement membrane beneath the endothelial cells lining 
the lumina. Immunohistochemical studies have documented increased 
expression of basic fibroblast growth factors21. Increase in vascular 
endothelial growth factor / vascular permeability factor has also been 
documented. The mast cells help in endothelial proliferation and are 
found in high numbers in proliferating hemangiomas22. 
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Involuting phase: 
 Regression is characterized by dilatation of vascular lumina, 
flattening of the endothelial cells and progressive deposition of 
perivascular fibrous tissue, which establishes a lobular architecture. 
Inhibition of matrix metalloproteinase, a protein that suppresses 
formation of new blood vessels also occurs during the involuting phase23. 
Involuted phase: 
 After regression is complete, all that remains are a few tiny, 
capillary like feeding vessels and draining veins, lined by flat, mature 
endothelium and surrounded by islands of loose fibrofatty tissue 
intermingled with dense collagen and reticular fibers23. 
 CLINICAL FEATURES: 
 Infantile hemangiomas are the commonest tumors of infancy, with 
a prevalence of about 4%-10% of full term white neonates; more often in 
girls (ratio 3:1 to 5:1) 24. They are less common in infants of African or 
Asian descent.  There is a higher incidence in infants born prematurely; 
about 13% at 1 year for all preterm infants, increasing in inverse 
relationship to birth weight5. At 1 year, the prevalence in preterm babies 
with a birth weight below 1500g is about 16%, and, in preterm babies 
with a birth weight below 1000g, about 23%. Conversely, the prevalence 
in preterm babies with a birth weight over 1500g is no different from that 
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of full-term babies. The prevalence of infantile hemangiomas at 1 year in 
preterm infants was shown to be inversely related to gestational age at 
birth, being recorded as 8% for babies born after the 35th week, 11% for 
those born between the 30th and 35th weeks, and 19% for those born 
between the 25th and 29th weeks25.   
 Infantile hemangiomas become apparent during the first month of 
life in about 90% of cases, and virtually 100% by the ninth month. 
Approximately 65% of infantile hemangiomas are superficial, 15% deep 
and 20% mixed6. Hemangiomas typically are single tumors, but 20% 
grow in multiple cutaneous sites, including other organ systems, notably 
liver, gastrointestinal tract, brain etc. Approximately 30%-50% of 
hemangiomas are nascent at birth, presenting as a barely visible pale spot, 
a telengiectatic/ macular red stain, or as a pseudoecchymotic patch. The 
term congenital hemangioma defines a tumor that is fully developed at 
birth and does not exhibit the usual postnatal rapid growth23.    
Proliferating phase: 
 The superficial infantile hemangioma is most commonly known as 
a strawberry nevus or strawberry hemangioma, on account of its usual 
clinical appearance in the form of a sharply circumscribed oval or round, 
soft, domed swelling of intense scarlet-red color as it permeates the 
superficial dermis. The surface may be smooth or lobulated. It is firm, 
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tense, and non-compressible. These lesions may occur at any site, but 
about 60% occur on the head and neck followed by trunk in 25%6.  
 If tumor spreads within the lower dermis, subcutis or muscle, 
however the overlying skin is only slightly raised, warm, and bluish in 
color. Draining veins are commonly seen radiating from the tumor. Hence 
there is frequently a deep element to superficial infantile hemangiomas of 
strawberry type, particularly when these are large; such lesions should be 
termed mixed infantile hemangiomas. Deep infantile hemangiomas often 
feel like a 'bag of worms', and a useful feature in their distinction from 
other tumors is that they can generally be compressed to about half their 
original size, quickly regaining their original dimensions on release of 
pressure. Similarly, they often become larger and darker when the child 
screams or cries6.    
 The growth of infantile hemangiomas typically begins to stabilize 
by 10 to 12 months. Spontaneous epithelial breakdown, crusting, 
ulceration, and necrosis complicate 5% of cutaneous hemangiomas26. 
Ulceration is less common than bleeding, although it is particularly likely 
to complicate lesions in the anogenital area, where it may result in 
dysuria or pain on defecation. Ulceration similarly tends to complicate 
lesions at other sites which are vulnerable to trauma, such as the ears, 
nose or the lips23.  
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Involuting phase: 
 Usually after 1 year, hemangiomas seem to grow in proportion to 
the child and then clinical signs of regression appear. Resolution of 
superficial infantile hemangiomas is heralded by softening of the lesion 
and by the appearance of opaque, pinkish grey areas in the centre of the 
surface. These foci gradually become confluent and extend towards the 
periphery of the lesion6.  
 Virtually 100% of infantile hemangiomas undergo spontaneous 
regression, which is complete or almost complete in about 95%. About 
30% of infantile hemangiomas lesions will have resolved by the fourth 
year, about 50% by the fifth and 75% by the seventh, gradual 
improvement continues till age 1227. The likelihood of early resolution is 
not affected by the size of the lesion, its site, or by the number of lesions 
present.  
Involuted phase: 
 Nearly normal skin is restored in approximately 50% of children. 
Stigmata of involuted infantile hemangioma include telengiectasias, and 
at certain sites, particularly the lips and eyelids, it is common for there to 
be a residual sac of redundant and slightly atrophic skin23. An early onset 
of resolution is generally associated with a more rapid disappearance and 
a superior cosmetic result. Conversely, a late start to resolution is 
generally associated with a higher chance of incomplete regression. Areas 
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of previous ulceration frequently leave yellowish scars. Lesions in the 
scalp usually resolve without permanent alopecia in the affected area, 
unless previous ulceration has occurred. Perhaps the commonest lesions 
that fail to show complete resolution are lesions on the nose, ears and 
lips6. 
COMPLICATIONS: 
Ulceration: 28 
 Ulceration is frequently complicated by infection, and when it 
occurs on the ears, nose or lips, permanent loss of tissue and mutilation 
may result, sometimes very rapidly. Recurrent bleeding may also 
complicate ulceration. Ulceration is likely to be followed by scarring. 
Haemorrhage: 
 Only rarely is bleeding from an infantile hemangioma substantial, 
except in the Kasabach-Merritt syndrome or during surgery. Normally, 
compression will stop bleeding6. 
Infection: 
 Secondary infection may complicate infantile hemangiomas in the 
event of ulceration or following any type of surgical interference. 
Occasionally, this may lead to septicaemia, with a potentially disastrous 
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outcome. Group A streptococci appear to be particularly dangerous in this 
situation6. 
Malignant change: 
 Although malignant change may be a complication of hepatic 
hemangiomas, it never complicates cutaneous infantile hemangiomas. 
However, true malignant vascular tumours in  infants might  conceivably  
be  initially  mistaken  for  infantile  hemangiomas, particularly  when  
they  have  a  deep  location.  Such tumours include malignant 
hemangioendotheliomas29 and malignant hemangiopericytomas30. 
Systemic hemangioma: 
 Visceral infantile hemangiomas may occur with or without 
coexistent cutaneous infantile hemangiomas. It may be found in liver, 
GIT, lung, spleen, pancreas, heart, kidneys, adrenals, bladder, brain etc. 
High-output cardiac failure is the commonest cause of death, and this is 
most often induced by arteriovenous shunting in the liver or lungs. Other 
complications included are the Kasabach-Merritt syndrome, convulsions, 
and obstructive jaundice6. 
Heart failure: 
 Shunting of large volumes of blood through infantile hemangioma 
may lead to high-output heart failure. This complication is particularly 
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likely to occur in association with multiple infantile hemangiomas, when 
it is usually due to shunting through one or more hepatic hemangiomas31. 
Kasabach meritt syndrome: 
 It is characterized by thrombocytopenia (due to platelet trapping), 
coagulopathy, and microangiopathic hemolytic anemia in association 
with a rapidly enlarging vascular lesion. It was traditionally felt to be a 
complication of infantile hemangiomas, but is now associated with 
different vascular tumors, namely kaposiform hemangioendothelioma32 
and tufted angioma33. 
 Infantile hemangiomas leading to the Kasabach-Merritt syndrome 
are generally single deep lesions of larger size, but the disorder can very 
occasionally occur in association with smaller and more superficial 
lesions. The responsible infantile hemangioma will most commonly occur 
on the trunk, neck and proximal parts of the limbs, particularly the thighs 
and shoulders and, relatively uncommonly, on the head. The coagulation 
defect almost always becomes apparent during the first few weeks of life, 
but may already be apparent at birth. The onset of defective coagulation 
is most commonly heralded by bleeding into and around the angioma or 
manifested by an increase in size, induration, tenderness and superficial 
ecchymoses. The resulting rapid expansion of the angioma may cause 
potentially lethal compression of neighbouring vital structures, 
particularly when the lesion is in the cervicofacial area6.  
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 In addition to thrombocytopenia other laboratory findings include 
anemia, hypofibrinogenemia, elevated D-dimers, fragmentation of 
erythrocytes on manual smear, and prolonged coagulation studies. The 
mortality rate is high, from 10-30%34. 
Impairment of vision: 
 Infantile hemangiomas involving the eyelids can interfere with 
vision in several ways. Firstly, obstructive amblyopia may result if the 
lesion directly obscures the line of vision. Secondly, such lesions may 
also lead to astigmatism, even when the line of vision is not obstructed, 
probably due to a direct pressure effect on the cornea; this can lead to 
astigmatic amblyopia35. 
Airway obstruction: 
 It is important to consider the possibility that any infant with a 
cutaneous hemangioma may concurrently have a subglottic hemangioma. 
This is most likely if the cutaneous lesion is in the neck, from which there 
may be direct extension into the subglottic airway. Such an event may 
require an emergency tracheotomy for its relief. Involvement of the nose 
in the neonatal period may also obstruct respiration, as neonates normally 
will not breathe through the mouth36. 
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Interference with feeding: 
Feeding difficulties may complicate hemangiomas in the mouth 
and those that obstruct nasal breathing6. 
Obstruction of external auditory canal: 
 Hemangiomas that encroach on the ear may obstruct the external 
auditory canal. Although this will interfere with hearing in the short term, 
it will generally not affect the development of normal ear function in the 
longer term. Bilateral obstruction after the age of about 1 year would, 
however, be likely to interfere with normal speech development, but must 
be very rare6. 
Deformation of bone: 
 Minor deformities of bone occasionally results from direct pressure 
of an angioma, on the calvarium for example. Very rarely, large infantile 
hemangiomas of the face may provoke overgrowth of the facial skeleton 
or of the auricular cartilage6. 
Other associations:37 
 PHACES is one of the major associations. It includes Posterior 
fossa anomalies, Hemangioma, Arterial anomalies, Coarctation of aorta, 
Eye abnormalities, Spinal dysraphism and supra umbilical raphe. 
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DIAGNOSIS: 
1. By clinical presentation → Hemangioma is non-blanching; firm to 
rubbery on palpation. 
2.  Biopsy: 
 In the earliest phase of growth of infantile hemangiomas, there is a 
solid mass of proliferating endothelial cells, with few if any lumina. The 
nuclei are not pleiomorphic, and only occasional mitoses are visible. 
Later in the proliferative phase, capillary-sized lumina are apparent, lined 
by plump endothelial cells. Reticulin staining confirms that each group of 
endothelial cells is surrounded by a limiting membrane of reticulin fibres. 
Periodic acid-Schiff (PAS) staining shows a thickened basement 
membrane beneath the endothelial cells lining the lumina. Initially, these 
lumina are slit-like, but gradually they become more dilated. Mast cells 
are plentiful during the proliferative phase22.  
 The hemangioma becomes progressively more organized, with 
distinct lobules separated by fibrous septa containing the larger feeding 
and draining vessels. In older lesions the number of vascular channels 
decreases, and the diameter of the lumina increases with flattening of the 
endothelial lining, resulting in a 'cavernous' appearance, which must not 
be confused with the appearance of a venous malformation. There is a 
simultaneous progressive increase in intra- and interlobular connective 
tissue and fat23. 
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3.  Ultrasonography with colour flow imaging:38 
 It is useful in differentiating deep hemangioma from vascular 
malformations. The sonographic hallmark of proliferating phase 
hemangioma are dense parenchyma and fast flow. Hemangioma shows 
decreased arterial resistance, increased venous velocity on duplex 
evaluation and discrete soft tissue mass effect with conventional 
ultrasonography. 
 
4. MRI :39 
 
 It is the “gold standard” for evaluation of a vascular anomaly; 
however it generally requires sedation or general anaesthesia if child is 
less than 6 years of age. Hemangioma appears as a parenchymatous tissue 
of intermediate intensity on T1-weighted, spin- echo images and 
moderate hypertintensity on T2- weighted, spin echo images. Exact 
localization, extent of involvement and with midline lesions, Presence of 
associated cranial / spinal dysraphism can be readily identified. 
 
5. CT  
6. Placental markers:High Endothelial immunoreactivity for erythrocyte 
type GLUT 1, merosin1, Lewis Y antigen (LeY) and fc (γ) R II6.  
 
  
 
20
TREATMENT: 
 In the absence of complications or where there is substantial 
cosmetic handicap, the correct management of infantile hemangiomas is 
generally expectant. No treatment is indicated where a good cosmetic 
result can be predicted34.  
 Following are the considerations for evaluation, referral, and /or 
therapy34: 
¾ Life threatening 
¾ Interfering with vital functions 
 Periocular 
 Nasal tip 
 Ear (extensive) 
 Lips 
 Genitalia, perineum 
 Airway 
 Hepatic 
¾ Large facial 
“Beard” distribution 
¾ Ulcerating 
¾ Multiple 
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 Treatment options include: (i) systemic corticosteroids; (ii) 
intralesional corticosteroids; (iii) topical corticosteroids under occlusion; 
(iv) laser therapy; (v) compression; (vi) surgical excision; (vii) 
embolization; (viii) vincristine; (ix) cryotherapy; (x) interferon (xi) 
sclerosant injection; and (xii) radiotherapy. 
Treatment of ulceration or bleeding: 
 Ulcerated hemangioma is treated with daily cleansing, application 
of hydrated petrolatum, a topical antibiotic, or a hydrocolloid dressing 
and viscous lidocaine. Superficial ulceration usually heals within days to 
weeks; a deep ulceration can take longer. Flashlamp pulsed- dye laser is 
reported to aid healing and alleviate pain associated with ulcerated 
lesions40. 
 Complete resection may be the most expeditious treatment, usually 
indicated for tumor located in scalp, chest, or extremity, but rarely for a 
facial lesion. If does bleeding occur, parents should be instructed to 
compress the bleeding area with a clean pad, holding pressure for exactly 
10 minutes. Local tamponade controls bleeding in most circumstances; 
occasionally a suture is needed to control a bleeding site23. 
Corticosteroids:  
 Oral and intralesional corticosteroids are effective at slowing the 
growth and decreasing the size of proliferating infantile hemangiomas. 
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The mechanism of action has not been elucidated completely; however, 
corticosteroids appear to act by potentiating vasoconstrictive effects of 
epinephrine and norepinephrine on vascular smooth muscle. Evidence 
indicates that corticosteroids block estradiol receptors in hemangiomas in 
vitro. Response vary widely, from less than 40% to greater than 90%, 
depending on dose, duration of treatment, and age at which corticosteroid 
therapy is initiated41. Corticosteroid therapy should be administered 
during the proliferative phase because it has a negligible effect on 
involuting and otherwise stable infantile hemangiomas. The oral route 
generally is preferred over intralesional therapy; however, the location, 
size, patient age, and physician experience factor into the decision-
making process. Prednisolone is initially given at 2to 3 mg/kg/day23. 
 Intralesional corticosteroid should be considered for a small, well- 
localized cutaneous hemangioma and typically for lesions located in the 
nasal tip, cheek, lip, or eyelid. The goal is to minimize the volume of the 
proliferating tumor. Triamcinolone (2 to 3 mg/kg) is injected slowly at 
low pressure. On average, three sessions are needed at 6-8 week intervals. 
It has been suggested that potent topical steroids under occlusion may be 
an effective treatment approach for certain infantile hemangiomas23. 
Laser therapy: 
 Laser surgery is beneficial in treating both proliferating and 
residual vessels from hemangiomas. The flashlamp-pumped pulsed-dye 
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laser has become the most widely used laser for selective ablation of 
vascular tissue in childhood.  Pulsed-dye laser surgery is effective for 
treating ulcerated hemangiomas and thin superficial hemangiomas, 
especially those on areas likely to result in significant functional or 
psychological impact (eg, fingers, eyes, lips, nasal tip, ears, face) 42. Many 
ulcerated hemangiomas respond with decreased pain (sometimes as early 
as a few days after the initial treatment), rapid reepithelialization, and 
hastened involution.  
 Treatments generally are performed every 2-4 weeks until 
complete healing results. Occasionally, particularly with deep or 
combined superficial and deep lesions, ulceration may worsen with 
pulsed-dye laser treatment43. 
 The risk of scarring or residual skin changes associated with 
pulsed-dye laser surgery of hemangiomas may be greater than without 
early laser treatment or with the treatment of capillary malformations, but 
the benefits of early involution should be weighed against the risks of a 
passive approach or alternative therapies. Other lasers that appear to be 
efficacious in treating hemangiomas include the pulsed Nd:YAG, 
frequency-doubled Nd:YAG. Carbon dioxide lasers are occasionally used 
for airway hemangiomas44. 
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Surgical therapy: 
 The following are the indications for excision of infantile 
hemangiomas: 
¾ Ulceration or repeated bleeding 
¾ Redundant folds of atrophic skin 
¾ For eyelid lesions that have not responded adequately to oral or 
intralesional corticosteroids 
¾ At specific sites- for example at nasal tip45. 
Beta-adrenergic blocker: 46,47 
 Beta-blockers, most specifically propranolol, have been recently 
used for infants with severe or disfiguring hemangiomas. Most infants 
reported have been treated with propranolol at a dose of 2-3 mg/kg/d in 2-
3 divided doses. Duration of therapy varies from 2-10 months. As early as 
24 hours after the initiation of therapy, many infantile hemangiomas have 
begun to change from intense red to purple, with evidence of softening. 
Most continue to improve until nearly flat and with significantly 
diminished color. 
 The mechanism of action is unknown; however, some 
hypothesize that local vasoconstriction may be a factor, which is based on 
the early color change and softening of the lesion. One study has 
demonstrated that nonspecific and beta2-selective blockers (eg, 
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propranolol) triggered apoptosis of capillary endothelial cells in adult rat 
lung tissue, suggesting a similar mechanism may be plausible for 
hemangioma endothelial cells.  
Interferon alfa-2a or Interferon alfa-2b:48,49 
 Recombinant interferon should be considered the second line drug 
for endangering or life threatening hemangioma. Indications for IFN 
therapy include failure of response to corticosteroid, contraindication to 
prolonged systemic steroids, complications of steroid and rare instance of 
parental refusal to use corticosteroids. 
 The empirical dose of IFN is 2 to 3 million U/m2, injected 
subcutaneously every day for 6 to 12 months. Side effects of IFN include 
elevated hepatic enzymes, transient neutropenia, and anemia. The most 
serious toxicity of IFN is spastic diplegia, which occurs in an estimated 
5% of cases. 
Biologic immune response modifiers: 50,51 
 Topical Imiquimod cream is the only medication in this new class. 
It works by stimulation of toll-like receptor 7 (TLR-7) and increases local 
interferon alpha and gamma, through which it may exert antiangiogenic 
effects. In a mouse model, imiquimod-treated vascular tumors showed 
decreased tumor cell proliferation, increased tumor apoptosis, and 
increased expression of tissue inhibitor of matrix metalloproteinase-1, 
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with decreased activity of matrix metalloproteinase-9, both of which are 
observed in the natural involution of infantile hemangiomas. The other 
modalities include sclerotherapy, vincristine, embolic therapy etc. 
CONGENITAL HEMANGIOMAS: 
 These are unusual tumors that have no female predominance and 
are fully grown in utero and do not have a postnatal growth phase. They 
differ from infantile hemangioma by their clinical features, pathology and 
their negative immunophenotyping for the placental markers52. They are 
further categorized into 2 types namely RICH and NICH. 
Rapidly Involuting Congenital Hemangioma (RICH): 
 RICH appears as large, round or oval, bulging tumor, usually with 
a smooth surface and more often located on a limb close to a joint, on the 
forehead, cheek, scalp. Prominent telengiectasias are often seen on the 
surface, centre of the lesion is either nodular or necrotic and the mass is 
encircled by a white ring or halo. Spontaneous regression occurs within 
6-14 months53. 
 RICH are detected during prenatal ultrasound during third trimester 
and sometimes even as early as 16th week of gestation. It appears as an 
exophytic, hypoechoic mass traversed by multiple compressible channels 
with a predominantly venous flow54. Antenatal MRI is recommended to 
define the better characteristics of the vascular tumor. The pathologic 
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features of a RICH include large and small lobules of vessels embedded 
in fibrosis, as well as extralobular vessels. Some vessels have moderately 
plump endothelium; endothelial cells are negative for GLUT-153. 
Non-Involuting Congenital Hemangioma (NICH): 
 A NICH is less impressive at birth than a RICH. The tumor is 
usually flat, and round or oval in shape. The centre varies from pinkish 
with minor telengiectasia and the location is similar to those of RICH. 
After birth NICH is fast flow by Doppler evaluation. And it may reveal 
minor arteriovenous fistulas. The pathology of a NICH includes rather 
large lobules made of small capillaries lined by endothelial cells with 
hobnail nuclei. Lobules are separated by dense fibrous tissue. Endothelial 
cells lack reactivity for GLUT-155. Unlike a RICH, a NICH never 
involutes. 
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VASCULAR MALFORMATIONS 
 Vascular malformations can be localized or diffuse errors of 
embryonic development. The classification of these anomalies is based on 
the type of abnormal vascular channels and flow characteristics. The term 
vasculogenesis refers to the processes by which mesodermally derived 
endothelial precursors align to form primitive blood vessels. The term 
angiogenesis refers to the formation of new vessels from pre-existing 
vessels. The various types of vascular malformations can be envisioned 
as faulty development at some stage of either vasculogenesis or 
angiogenesis23. Most vascular malformations are sporadic, but some are 
inheritable in a classic mendelian autosomal dominant pattern. Molecular 
studies suggest that vascular anomalies are caused by dysfunctional 
signaling processes that regulate proliferation, apoptosis, differentiation, 
maturation, and adhesion of vascular cells56. 
CAPILLARY MALFORMATIONS: 
 CMs are composed of dilated capillary to venule sized vessel in the 
superficial dermis. It includes salmon patch and portwine stain. 
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SALMON PATCH: 
 syn. Naevus simplex; erythema nuchae; unna's naevus; 'stork bite'; 
'angel's kiss 
 Salmon patches' are extremely common anomalies, which have 
been observed in the neonatal period in about 20-60% of children of all 
races57. There is evidence of a definite genetic influence in their 
aetiology, and both nuchal and facial salmon patches seem to be inherited 
in an autosomal dominant manner58. Clinically, the lesions take the form 
of irregular, dull, pinkish red, macular areas, often featuring fine, linear 
telangiectasia. The nape of the neck is by far the most commonly affected 
site, but facial lesions, on the glabella, forehead, upper eyelids, tip of the 
nose or upper lip are also frequent. Those on the face fade rapidly, and 
most will have more or less disappeared within a year. Nuchal lesions 
tend to be much more persistent, and probably remain unchanged into 
adult life in at least 30% of cases6. 
PORTWINE STAIN: 
Syn. Naevus Flammeus 
 PWS is a congenital capillary malformation that may occur as an 
isolated lesion or in association with a variety of syndromes. These 
lesions present as macular stains with a pink to dark red color. Although 
an early PWS may be indistinguishable from an infantile hemangioma, 
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these lesions are usually distinguished by their congenital presence and 
their static nature, without the rapid proliferation and thickening that 
characterizes hemangiomas during the first year of life34.  
Etiology: 
 Capillary malformations and other vascular malformations are the 
result of abnormal morphogenesis. They are characterized by ectatic 
papillary dermal capillaries6. These ectatic vessels are lined by flat, 
benign-appearing endothelial cells, similar to the vessels of normal skin, 
with similar staining characteristics for endothelial antigens, including 
fibronectin, von Willebrand factor, and collagenous basement membrane 
proteins. The endothelial cells also exhibit cell turnover similar to normal 
vessels, supported by a paucity of mitoses or an uptake of tritiated 
thymidine. 
 Evidence supports a neural role in both the development and 
progression of capillary malformations. Animal studies show that the 
sympathetic nervous system influences the composition and functional 
properties of the vessel wall during development23. 
 Immunohistochemical studies of capillary malformations reveal a 
significantly decreased density of perivascular nervous tissue in lesional 
skin, suggesting that inadequate innervation may be responsible for 
decreased vascular tone and progressive vascular dilatation59. Confocal 
microscopic studies demonstrate an inverse correlation between nerve 
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density and blood vessel diameter and evidence that capillary 
malformations with the lowest nerve density exhibit the highest blood 
vessel density and the poorest response to laser intervention60.  
 The potent endothelial cell mitogen vascular endothelial growth 
factor (VEGF)–A and its most active receptor VEGF-R2 expression are 
significantly increased in capillary malformation skin tissue compared 
with control skin61. This may suggest that VEGF and VEGF-R could 
contribute to the pathogenesis of capillary malformations by inducing 
vessel proliferation and/or vasodilatation. If this is indeed a pathogenic 
factor, antiangiogenic treatments using VEGF blocking agents may prove 
to be useful for capillary malformations. Tie2 and angiopoietin-1 are 
known regulators of vascular remodeling during angiogenesis, mutations 
of which have been demonstrated in familial venous malformations62. 
 An inactivating mutation of RASA1 on 5q has been detected in 
some kindreds with multiple, small, round-to-oval, pink capillary 
malformations. RASA1 encodes a GTPase-activating protein, which 
negatively regulates Ras activity63.  
 Occasionally, lesions that appear to be identical to congenital port-
wine stains have made their initial appearance in adult life, and may have 
followed trauma, possibly as a result of damage to the microvascular 
nerve supply. Familial multiple telangiectatic naevi having the 
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appearance of small port-wine stains have been reported on several 
occasions6. 
Clinical features: 
 Port wine stains are almost always present since birth. The reported 
incidence in the newborn has been from 0.1 to 2%. They vary in colour 
from a fairly pale pink to a deep red or purple, and in size from a few 
millimetres to many centimetres in diameter. PWS may progressively 
darken over many years, and occasional lesions develop secondary 
proliferative vascular blebs on their surface (cobble stone appearance) 64. 
They may also become thickened and later in life. Port wine stains are 
often, but not always, unilateral and the most common site of 
involvement is the face, although they may occur on any cutaneous 
surface. In the face, there can be enlargement of the affected lip and 
gingival, and usually the maxilla or the mandible. In the limb, it is 
associated with limb hypertrophy both in length and girth. Associated eye 
and brain abnormalities occur in 8-15% of patients with facial port-wine 
stains65.  
 Port-wine stains are not infrequently associated with adjacent areas 
of naevus anaemicus, and it has been suggested that this phenomenon 
may be explained by somatic recombination66. 
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Treatment: 
 PWS lesions show little tendency toward spontaneous 
improvement or involution, and traditional therapy was limited to the use 
of tinted “cover-up” cosmetics. Laser therapy has revolutionized the 
treatment of these lesions, most notably the flashlamp pumped tunable 
pulsed dye laser. Flashlamp-pumped pulsed-dye laser (PDL) surgery is 
the treatment of choice for capillary malformations. It uses selective 
photothermolysis with ultrashort pulses of monochromatic yellow light 
(585-600 nm), which are preferentially absorbed by oxyhemoglobin in 
the abnormally dilated superficial dermal blood vessels. Flashlamp-
pumped PDL causes selective destruction of these superficial target blood 
vessels, inducing intravascular coagulation and rupture of some smaller 
vessels, which later become absorbed and replaced by collagen. The 
ultrashort laser pulses are shorter than the thermal relaxation time of the 
vessels, thereby limiting adjacent dermal and epidermal heating and 
preventing subsequent damage. PDL therapy is usually performed over 
several sessions, separated in time by 6-8weeks, and can be quite 
effective in lightening these lesions67.  
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STURGE WEBER SYNDROME: 
Syn. Encephalofacial Angiomatosis 
 It is a neuroectodermal syndrome characterized by a PWS in the 
distribution of the first (ophthalmic) branch of the trigeminal nerve (V1) 
in association with leptomeningeal angiomatosis (presenting usually with 
seizures) and glaucoma. There are rare reports of patients with classic 
brain and ophthalmic findings in the absence of facial PWS65. 
 PWS may also have multidermatomal or more extensive cutaneous 
involvement. In most cases, neurological symptoms have their onset 
during the first 2 years of life, and their first appearance after the age of 6 
years is unusual. Some patients with extensive leptomeningeal 
angiomatosis remain asymptomatic throughout life. Seizures are the most 
common CNS feature, and often have their onset during the first year of 
life. The seizures are difficult to control, and both early onset and 
increased seizures intensity are associated with future developmental and 
cognitive delay34.  
 Ocular involvement occurs in around 60% of patients with SWS. 
Glaucoma is the most frequent ocular finding, and it may be present at 
any time between birth and the fourth decade. It may be unilateral or 
bilateral. Vascular malformations of the eye in patients with SWS may 
involve the conjunctiva, episclera, choroid, and retina. Other eye findings 
include nevus of ota, buphthalmos, and blindness34. 
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 The EEG shows suppression of cortical activity over the affected 
area which may or may not be associated with focal epileptiform spike 
discharges. Cortical calcifications can generally be seen radiologically as 
sinuous, double-contoured lines running with the cortical convolutions on 
the affected side, but this change is generally absent in infancy and, in a 
proportion or cases, throughout life. However, intracranial calcification is 
generally visible by CT scanning, especially when enhanced by contrast 
injection, within the first few months of life68. Gadolinium-enhanced MRI 
scans are now considered to be the superior technique for the detection of 
the angiomatosis, definition of its extent and of associated vascular 
anomalies, assessment of the degree of parenchymal atrophy and of 
ischaemic damage69. 
 Although the primary management for seizures is with 
pharmacologic agents, surgical therapy may become necessary. 
Hemispherectomy is often advised for patients with intractable seizures 
and unihemispheric involvement70. 
KLIPPEL - TRENAUNAY SYNDROME: 
 It is a sporadic disorder characterized by the triad of vascular 
malformations, venous varicosity, and hyperplasia of soft tissue and bone. 
The vascular malformation is most often a capillary malformation of the 
portwine stain type. The lower extremity is the most common location 
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involved71. When arteriovenous malformations are also present; patients 
have to be invariably referred to as having Parkes-Weber syndrome34. 
 However, in addition, it is characteristic for other, often large or 
complex vascular malformations to co-exist with the port-wine stain. 
Perhaps lymphangioma circumscriptum is the most typical of all, but 
deep lymphatic and/or venous malformations are also relatively 
common72. The latter are most likely to have been present since birth. 
Lymphoedema is also common, and may be accompanied by recurrent 
bouts of cellulitis. 
 Complications include thrombophlebitis, coagulopathy, 
compensatory scoliosis and hip dislocation34. Treatment is mainly 
supportive. The clearest indication for surgical therapy is leg length 
discrepancy, which is projected to exceed 2 cms at skeletal maturity and 
which can be treated with epiphysiodesis in growing child73. 
PROTEUS SYNDROME: 
 The Proteus syndrome comprises an association of asymmetrical 
overgrowth of almost any part of the body, verrucous epidermal naevi, 
infantile haemangiomas and lipoma-like subcutaneous hamartomas74. 
Macrodactyly has been regarded as particularly characteristic, but should 
not be considered necessary to the diagnosis. The rugose or cerebriform 
overgrowth of the plantar and/or palmar soft tissues on a hypertrophied 
foot and/or hand seems to be highly distinctive. Macrocephaly and/or an 
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excessive linear growth rate are also common findings. Other skin 
findings have included café-au-lait macules and macular 
hypopigmentation, which may be of a linear or whorled type74. 
 Other non-cutaneous findings have included skeletal abnormalities, 
such as exostoses, kyphosis, scoliosis and spinal canal stenosis leading to 
spinal cord compression, ocular abnormalities including congenital 
blindness, epibulbar tumours, enlargement of the eye, cataract and 
strabismus, misshapen teeth, hypodontia etc6. 
PHAKOMATOSIS PIGMENTOVASCULARIS:75 
 The word phakomatosis has come to imply simultaneous 
involvement by a developmental malformation syndrome of eye, skin and 
CNS. The rather clumsy term, phakomatosis pigmentovascularis, has 
been proposed for a syndrome combining vascular malformations of port-
wine stain type, oculocutaneous melanosis and CNS manifestations such 
as seizures and hemiplegia . 
Type I: port-wine stain and linear epidermal naevus 
Type II: port-wine stain and dermal melnocytosis 
Type III: port-wine stain and naevus spilus 
Type IV: port-wine stain, dermal melanocytosis and naevus spilus 
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Cobb syndrome: 
 In Cobb syndrome (cutaneomeningospinal angiomatosis), a 
cutaneous vascular lesion in the skin overlying the spine, is associated 
with vascular malformations (venous or arteriovenous) in the subjacent 
spinal meninges34.  
Wyburn-Mason syndrome: 
 Wyburn-Mason syndrome (unilateral retinocephalic syndrome), 
also known as Bonnet-Dechaume-Blanc syndrome, manifests as facial 
capillary malformations associated with unilateral AVM of the retina and 
the intracranial optic pathway. Capillary malformations may occur 
anywhere on the ipsilateral face (not just the eyelids or periorbitally), and 
they may have associated facial hypertrophy or occasional involvement 
of the optic chiasm, the hypothalamus, the midbrain, and the basal 
ganglia, with associated mental retardation or neurologic signs and 
symptoms6. 
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AIM OF THE STUDY 
1. To study the incidence of hemangiomas and vascular 
malformations. 
 
2. To study the age of onset of hemangiomas and vascular 
malformations. 
 
3. To study the sex distribution of hemangiomas and vascular 
malformations. 
 
4. To study the familial incidence of hemangiomas.  
 
5. To study the distribution of lesions.  
 
6. To study the complications. 
 
7. To study the associations. 
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MATERIALS AND METHODS 
 Patients attending the Department of Dermatology, Madras 
Medical College during the period August 2007- September 2009 were 
screened for hemangiomas and vascular malformations and those were 
the subjects of a descriptive study. The clinical findings were recorded in 
a proforma. The parameters noted were age, sex, age of onset, reason for 
visiting the hospital, family history, duration of lesion, site of 
involvement, morphology of lesions, number of lesions, and associated 
findings. In addition to the presenting symptoms, a skin biopsy was done 
wherever necessary. Relevant investigations were carried out for any 
systemic association. The results obtained were tabulated and analyzed.  
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OBSERVATIONS AND RESULTS 
 A total of 52,369 cases attended the dermatology OPD during the 
study period from August 2007 to September 2009. Out of these, 56 cases 
(0.11%) were found to have vascular naevi. Thirty six of them were 
hemangiomas and twenty cases were port-wine stains. 
Presenting age group of vascular naevi: 
 Of the 56 cases with vascular naevi, patients with hemangioma 
presented early and were mostly within 5 years of age.  Vascular 
malformations though present since birth, the presenting age group was 
mostly above 10 years. 
Table 1 
Vascular naevi 0-5 years 5-10 years >10 years 
Hemangioma 34 2 - 
Vascular Malf. 1 1 18 
 
 
42
 
HEMANGIOMA: 
Incidence: 
 Hemangiomas accounted for 36 (64.29%) of all the 56 cases of 
vascular anomalies. 
 
Hemangioma
Vascular 
malformations
Vascular Anomalies
 
Figure 1 
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AGE DISTRIBUTION: 
 Of the 36 cases in the study, 30 cases had lesions at birth, 4 cases 
had appearance of the lesion at 1st month, one case had appearance of 
lesion at 2nd month, and one case had development of lesion by 3rd month. 
Table 2 
Age of onset Male Female Percentage 
At birth 6 24 83.33% 
1st month 1 3 11.11% 
2nd month 1 0 2.78% 
3rd month 0 1 2.78% 
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SEX DISTRIBUTION: 
 There was a female preponderance with female patients numbering 
28(77.78%) and male patients numbering 8(22.22%) of the total 36 cases. 
     Table - 3 
Sex No. of cases Percentage 
Male 8 22.22% 
Female 28 77.78% 
 
 
Figure 3 
FAMILY HISTORY: 
 Out of the 36 cases a positive family history in either the parents or 
the siblings was present in 4 cases (11.11%). 
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BIRTH (NATAL) HISTORY: 
 Among the observed 36 cases, 7(19.44%) had a history of pre term 
birth occurring before 36 weeks. One case out of these 7 cases was 
delivered even before 32 weeks. The birth weight obtained by history 
accounted that 4 cases (11.11%) were between 1500gm- 2500gm and 1 
case (2.77%)  was even below 1500gm and the infant was intervened 
with oxygen therapy due to faulty breathing. 
Table 4 
Time of delivery No. of cases Percentage 
< 32 weeks 1 2.78% 
32-36 weeks 6 16.67% 
>36 weeks 29 80.55% 
 
 
Figure 4 
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Table 5 
Birth weight No. of cases Percentage 
< 1500gm 1 2..78% 
1500-2500gm 4 11.11% 
2500gm> 31 86.11% 
 
 
Figure 5     
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NO. OF LESIONS:  
Single lesion was present in 32 cases (88.89%) while rest of the 4 cases 
(11.11%) had multiple lesions. 
     Table 6 
No.of lesions No. of cases Percentage 
Single 32 88.89% 
Multiple 4 11.11% 
 
 
Figure 6 
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LESION SUBTYPE: 
 Localized lesions were the most commonly encountered type in 24 
cases (66.67%). Segmental type was seen in 5 cases (13.89%), 
indeterminate type was observed in 6 cases (16.67%) and 1 case (2.78%) 
had multifocal type. Complications were mostly seen in segmental type. 
Table 7 
Lesion type No. of cases Percentage 
Localised 24 66.67% 
Segmental 5 13.89% 
Indeterminate 6 16.67% 
Multifocal 1 2.78% 
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DISTRIBUTION OF LESIONS: 
 The most common site of involvement is head and neck in 16 cases 
followed by trunk in 9 cases and extremities in 9 cases. One case had the 
involvement of genitalia. One case had mutifocal involvement.  
Table 8 
Area of involvement No. of cases Percentage 
Head and neck 16 44.44% 
Trunk 9 25% 
Extremities 9 25% 
Genitalia 1 2.78% 
Multiple  1 2.78% 
 
 
Figure 8     
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COURSE OF THE LESION: 
 In our study out of the 36 cases, 11 cases (30.56%) were in 
progressive phase, 21 cases (58.33%) were in  non-involuting phase and 
only 4 cases (11.11%) were in the involuting stage while no case had 
complete involution during the study period. 2 cases were operated owing 
to their bleeding and ulcerative complications. 
Table 9 
Course No. of cases Percentage 
Progressive 11 30.56% 
Non-involuting 21 58.33% 
Regressive 4 11.11% 
 
 
Figure 9 
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COMPLICATIONS: 
 In our study out of 36 cases, 11 cases presented with various 
complication. 6 cases (16.67%) had ulceration, 3(8.33%) had bleeding 
complication, feeding and breathing difficulty in 2(5.56%) and 1 case had 
occlusion of eye.  
Table 10 
Complications No. of cases(n=36) Percentage 
Ulceration 6 16.67% 
Bleeding 3 8.33% 
Feeding and Breathing 
difficulty 
2 5.56% 
Vision impairment 1 2.78% 
         
 
         Figure 10 
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RARER ASSOCIATIONS AND PRESENTATIONS: 
 One case was associated with occlusion of vision and with 
hydrocephalus and CT showed posterior fossa malformation in the form 
of Dandy Walker malformation. Cardiac evaluation of the child was 
normal. 
 One case presented with hemangioma involving the left cheek with 
stridor. MRI revealed subglottic extension of hemangioma and the patient 
was referred to ENT department and was suggested observation without 
any active intervention till 3 years of life. During the one year follow up, 
child was relieved of stridor and was comfortable. 
INVESTIGATIONS: 
 Baseline investigations were done in all the patients and they were 
within normal limits. 
 X-ray and CT scan were taken in specific cases and one case 
showed Dandy Walker malformation. 
 MRI was done in 2 cases and one case revealed subglottic 
involvement. 
 Biopsy was done in 3 patients and it was consistent with the 
diagnosis of hemangioma. 
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VASCULAR MALFORMATIONS 
Incidence: 
 Vascular malformations accounted for 20 cases (35.71%) of all the 
56 vascular anomalies observed. 
Age of onset: 
 All the 20 cases in our study had the presence of lesions since 
birth. 
Sex distribution: 
 Of the 20 cases in the study 9 were males (45%) and 11 were 
females (55%).  
Table 11 
Sex No. of cases Percentage 
Male 9 45% 
Female 11 55% 
 
 
Figure 11 
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DISTRIBUTION OF LESIONS: 
 Out of the 20 cases, 15 cases (75%) had the involvement of face, 
followed by extremity involvement in 4 cases (20%), while 1case (5%) 
had involvement of the back. 
Table 12 
Site of involvement No. of cases Percentage 
Face 15 75% 
Extremities 4 20% 
Back 1 5% 
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NO. OF DERMATOME INVOLVEMENT: 
 In our study 7 cases (35%) had unidermatomal involvement and 13 
cases (65%) had more than one dermatomal involvement. 
      Table 13 
 No. of cases Percentage 
Unidermatome 7 35% 
Multidermatome 13 65% 
 
 
Figure 13 
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DISTRIBUTION OF FACIAL LESION: 
 Of the facial involvement in 15 cases, extensive and bilateral 
involvement was present in 3 cases (20%), the rest 12 cases (80%) had 
unilateral involvement. 
 
Figure 14 
MUCOSAL INVOLVEMENT: 
 Of the 15 cases with facial involvement adjacent mucosa was 
involved in 6 cases (40%). 
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TRIGEMINAL NERVE INVOLVEMENT: 
 Portwine stain was mostly observed in the maxillary distribution 
alone in 8 cases (53.33%) and ophthalmic branch was involved in 2 cases 
(13.33%), maxillary and ophthalmic branch was involved in 1 case 
(6.67%) and all the three branches were involved in 4 cases (26.67%). 
Table 14 
Trigeminal Branch No. of cases Percentage 
Ophthalmic 2 13.33% 
Maxillary 8 53.33% 
Oph, Max 1 6.67% 
Oph, Max, Man 4 26.67% 
 
.  
Figure 15 
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COMPLICATIONS ASSOCIATED WITH FACIAL 
INVOLVEMENT: 
 Of the 15 cases with facial involvement, 5 cases (33.33%) had 
either ocular complication or CNS involvement or both. Out of the 3 
cases with bilateral distribution, 2 cases (66.67%) and of the 12 cases 
with unilateral distribution, 1 case (8.33%) had glaucoma. Among the 3 
cases with extensive & bilateral involvement, 2cases (66.67%) and 1case 
(8.33%) of unilateral distribution had a positive history for CNS 
involvement in the form of seizures. But all the three cases had normal 
CT finding. 
Table 15 
Distribution of lesions / 
Complications 
No. of cases 
 
Unilateral with CNS inv. 1 
Unilateral with Glaucoma 1 
Bilateral with CNS inv. 1 
Bilateral with glaucoma 1 
Bilateral with CNS inv and 
glaucoma 
1 
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OTHER PRESENTATIONS: 
 Klippel Trenaunay Syndrome was noted in two of the patients. 
These patients had increased limb length and increased girth compared to 
the normal limb and both cases had gait disturbance. Venous varicosity 
was evident in the affected limb in both cases by Doppler study.  
 Phakomatosis pigmentovascularis was observed in three cases. One 
case was associated with naevus of ota and congenital melanocytic naevi. 
One case was associated with congenital melanocytic naevi and the other 
case was associated with linear epidermal naevus. 
INVESTIGATIONS: 
 Baseline investigations were done in all the patients and they were 
within normal limits. 
 X- Ray of the affected part was taken in selective cases and in 2 
cases with Klippel Trenaunay syndrome there was increased limb length 
with soft tissue swelling.  
 MRI was done in 2 patients and in one patient it revealed a 
pituitary microadenoma.  CT scan was done in selective patients and was 
within normal limits. Ophthalmic opinion was sought in patients with 
facial involvement and among them three patients were found to have 
glaucoma.  
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DISCUSSION 
 In our study 56 cases presented with vascular naevi. The most 
common presenting age group of hemangiomas was below 5 years. 
Vascular malformations though present since birth, presenting age was 
only after 10 years of age. 
HEMANGIOMAS 
 Infantile hemangiomas are the commonest tumors of infancy, with 
a prevalence of approximately 1-3% after the first few days of life and 
approximately 10% by the end of the first year. In our study, 
hemangiomas were seen in 36 cases. 
 Hemangiomas are often absent or small at birth and grow rapidly at 
a rate beyond the child's growth followed by slow involution, often 
leading to complete regression. In the study of 327 patients of 
hemangioma by Chiller et al.76 a total of 36% of patients had lesions at 
birth, whereas 40% developed lesions within the first month of life. In 
Senthilkumar et al.77 study of 17 cases, 13 (76.5%) cases were present at 
birth and remaining 4 (21.1%) cases appeared up to 1 year of age. In our 
study of 36 cases of hemangioma, 30(83.33%) cases were present at birth 
and of remaining 6 (16.67%) cases, 4 cases had appearance of lesion at 1 
month, 1 case started developing lesion at 2nd month and 1 case had 
lesion from 3rd month. Thus in our study, almost all cases developed 
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their lesions within three months of life, which is comparable to other 
studies in which cases also there was an early onset of hemangioma. 
 Girls are more frequently affected than boys in the ratio of 3:124, 
except in small preterm infants where it is closer to 1:1. In Chiller et al. 
study, there were 79% girls and 21% boys with a female to male ratio of 
3.7:1. In Senthilkumar et al. study females (76.5%) were much more 
frequently affected than males (23.5%), with a sex ratio of 3.3:1. 
Similarly, we found females 28(77.78%) to be more frequently affected 
than males 8(22.22%) with a sex ratio of 3.5:1. Chiller et al. documented 
a positive family history of hemangioma in 10% cases, whereas in our 
study there were 4(11.11%) patients with family history of hemangioma.  
 The prevalence of infantile hemangiomas at 1 year in preterm 
infants was shown to be inversely related to gestational age at birth, and it 
occurs more commonly in infants born before 36 weeks25. In our study 7 
cases (19.44%) were born before 36 weeks and among the 7 cases, one 
case was born even before 32 weeks. Hemangioma also was also found to 
be increasing in inverse relationship to birth weight with increased 
prevalence in infants weighing less than 1500 gm at birth25. In our study 
4(11.11%) cases were found to have low birth weight between 1500-
2500gm. Only 1 case (2.77%) had birth weight less than 1500gm. 
 Mostly hemangiomas occur as a single lesion78. In Senthilkumar et 
al. study only 8 (47.1%) were solitary, the remaining 9 (52.9%) were 
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multiple. But in our study 32(88.89%) were solitary and the remaining 
4(11.11%) were multiple and this is in concurrence with other studies. Of 
the 4 cases, 3 cases had more than 2 lesions and 1 case had more than 10 
lesions. 
 In the study of Hemangiomas of infancy, Chiller et al. made a 
diagram (Figure 15) of the human body and gave a numerical value to 
each anatomic location. With the help of photographs of individual 
lesions or written descriptions, they mapped the individual lesions. 
Finally, they classified the lesions into localized, segmental, 
indeterminate, and multifocal. Localized lesions demonstrated clear 
spatial containment, usually with involvement of only 1 or 2 mapped 
sites. Segmental lesions demonstrated linear and/or geographical 
localization over a specific cutaneous territory and were usually 
associated with at least some plaque-like features. They were often 
unilateral and usually sharply demarcated at the midline, but there were 
exceptions, particularly nasal and lip lesions. The indeterminate lesions 
were hemangiomas that could not be confidently categorized as either 
localized or segmental. Hemangiomas were considered multifocal if the 
infant had eight or more individual noncontiguous lesions of any 
morphologic characteristic. In the study of 327 cases of hemangioma by 
Chiller et al., 227 cases were of the localized type, 78 cases were of the 
segmental type, 34 cases were of the indeterminate type, and 12 cases 
were of the multifocal type. In Senthilkumar et al study of 17 cases, 15 
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cases were of localized type and 2 cases were of multifocal type. In our 
study also localized type was most commonly observed among 24 cases 
(66.67%). Segmental type was seen in 5 cases (13.89%), indeterminate 
type was observed in 6 cases (16.67%) and 1 case (2.78%) had multifocal 
type. Of these, cases with segmental distribution had an increased 
incidence of complications which is in coherence with other studies. 
 Although hemangiomas may occur on any part of the body, they 
demonstrate a striking predisposition for the head and neck regions. In a 
large series, 60% of hemangioma occurred on the head and neck, 
followed by 25% on the trunk, and 15% on extremities79. In our study 
hemangiomas were distributed in head and neck in 16(44.44%), trunk 
9(25%), extremities 9(25%), genitalia in 1(2.78%), and multiple sites 
were involved in 1 case (2.78%). Thus as far as, single site of 
involvement is concerned, the most commonly involved site was head 
and neck, followed by trunk and extremities, which is comparable to 
earlier studies. 
 The growth characteristics of hemangioma are often divided into 3 
phases- proliferating, involuting, and involuted.  In Senthilkumar et al. 
study of 17 cases of hemangioma, 15 (88.2%) were progressive and two 
(11.8%) were non-involuting. Out of these 17 progressive cases, 11 
(64.7%) were progressing gradually and remaining 4 (21.1%) were 
progressing rapidly. In our study of 36 cases, 4 cases (11.11%) were in 
the involuting phase while 11 cases (30.56%) were in progressive phase 
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and 21cases (58.33%) were in non involuting phase. Of the 4cases in 
involuting phase, involution started after 1 year of age in 3 cases and after 
the 2nd year in 1 case. 
 Complications of hemangioma may result from their location, size, 
or rapid, proliferating phase. In the study of 327 cases by Chiller et al. 
40% of the lesions had some type of complication. Ulceration was 
observed in 75 lesions along with bleeding (usually minor) in 27, 
cutaneous infection in 14, and significant pain in 12. In Senthilkumar et 
al. study, four (23.5%) cases had some type of complication. Those 
complications included ulceration in all four cases and associated 
infection in a solitary case. In our study complications were present in 
11(30.56%), out of which 6(16.67%) had ulceration, 3(8.33%) had 
bleeding complication, feeding & breathing difficulty in 2(5.56%) and 
1(2.78%) had occlusion of vision. Thus, ulceration was the most common 
complication in our study as in other studies and it occurred following 
trauma. In our study complications were common with children born 
either preterm or with low birth weight or both. 
 In Chiller et al. study, the mucous membrane was involved in 10% 
cases76. In our study adjacent mucosal involvement was present in 4 cases 
(11.11%). But isolated mucosal involvement was not seen.  
 Associations observed in our study were, one case with 
hydrocephalus with occlusion of eye and other case showed subglottic 
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involvement in MRI. Excision was done in 2 patients with repeated 
ulceration.  Patient did not develop recurrence during the 1 year follow 
up. Child with subglottic involvement was referred to ENT department 
and was suggested observation and no active intervention till 3 years of 
age. During the follow up period child was relieved of stridor. 
VASCULAR MALFORMATIONS 
 Vascular malformations are localized or diffuse errors of 
embryonic development of which port-wine stain is a common vascular 
anomaly that is present at birth and persists throughout life. Out of the 56 
cases of vascular naevi in our study, portwine stain was observed in 20 
cases (35.71%). In our study all the 20 cases had the lesion since birth 
which is compatible with the literature. In B .Tallman et al80 study of 
portwine stain in 310 patients, 68% had more than one dermatome 
involved. In our study 7 cases (35%) had unidermatomal involvement and 
13 cases (65%) had more than multidermatomal involvement. 
 In B .Tallman et al study of 310 patients, extensive involvement 
with port-wine stain over the trunk and extremities as well as the head and 
neck, was observed in 12% and of the facial lesions 85% had unilateral 
and 15% had a bilateral distribution of their port-wine stain. In Juliette M. 
H.et al81 study of the prognosis of bilateral facial capillary malformation 
compared with that of unilateral facial port-wine stain in 350 patients 
7.71% of cases had bilateral distribution. In the series of 121 cases 
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reported by Bioxeda82 and colleagues, patients with bilateral distribution 
represented 14% total population of those with CM. In our study face was 
the most common site involved in 15 cases (75%), followed by extremity 
involvement in 4 cases (20%) while 1 (5%) had involvement of the back. 
Of the facial involvement in 15 cases, extensive and bilateral involvement 
was present in 3 cases (20%), the rest 12 cases (80%) had unilateral 
involvement. The adjacent mucosal involvement was present in 6 cases 
(40%) out of the 15 cases with facial involvement. 
 In Bioxeda et al study of 121 cases, 88% had involvement of 
maxillary division of trigeminal nerve either isolated or along with 
ophthalmic and mandibular division (Figure 16). In our study also 
Portwine stain had isolated involvement of maxillary distribution in 8 
cases (53.33%) and ophthalmic branch was involved in 2 cases (13.33%), 
maxillary and ophthalmic branch was involved in 1 case (6.67%) and all 
the three branches were involved in 4 cases (26.67%). The patients with 
CNS or Ocular complications or both had preferential distribution of the 
portwine stain over the maxillary branch of the trigeminal nerve. 
 In B .Tallman et al study 8% of all patients with trigeminal port-
wine stain had evidence of eye and/or central nervous system (CNS) 
involvement. In our study of the 15 cases with facial involvement 5 cases 
(33.33%) had ocular involvement or CNS involvement or both. 
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 In B .Tallman et al study 24% of those with bilateral trigeminal 
nerve port-wine stains had eye and/or CNS involvement compared with 
6% of those with unilateral lesions. In the Bioxeda et al study 26% of the 
patients with bilateral lesion had epilepsy, compared with 14% of those 
with unilateral lesions.  In our study out of the 3 cases with bilateral 
distribution, 2 cases (66.67%) and of the 12 cases with unilateral 
distribution, 1 case (8.33%) had glaucoma. Among the 3 cases with 
extensive & bilateral involvement,  2 cases (33.33%) and 1case (8.33%) 
of unilateral distribution had a positive history for CNS involvement in 
the form of seizures. But all the three cases had normal CT finding. 
 In our study 2 cases of Klippel Trenaunay Syndrome was observed 
and both cases had limb length discrepancy and also an increased limb 
girth. Phakomatosis pigmentovascularis was observed in 3 cases in our 
study, of which one case was found to be associated with linear epidermal 
naevi while one case was associated with both congenital melanocytic 
naevi and nevus of ota and other case had an association with congenital 
melanocytic naevi alone. 
 
      
 
 
 
68
CONCLUSION 
• Hemangiomas and vascular malformations were a rare occurrence 
constituting only 0.11% of all new cases attending the 
Dermatology outpatient department during the study period. 
 
• The incidence of hemangiomas was almost twice as much as that 
of vascular malformations. 
 
• Most of the hemangiomas had onset at birth while all vascular 
malformations were present since birth. 
 
• Hemangiomas had a female predominance, while in vascular 
malformations there was almost an equal sex distribution. 
 
• Familial incidence of hemangiomas was encountered in 11.11% 
cases. 
 
• The most common site of occurrence in hemangioma was head and 
neck followed by trunk, extremities, and genitalia; while in 
vascular malformation face was the most commonly involved site 
followed by extremities and trunk. 
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• Hemangiomas commonly presented with single lesion, and most 
cases were either in progressive or non involuting phase. 
Multidermatomal involvement was observed more often in 
vascular malformations. 
 
• Localized type of hemangiomas was most commonly observed 
while segmental type was most commonly associated with 
complications. 
 
• Port wine stain occurred most commonly over the distribution of 
maxillary division of trigeminal nerve. Patients with CNS or ocular 
complications or both had preferential involvement of maxillary 
branch. 
 
• Most frequently encountered complication in hemangiomas was 
ulceration followed by bleeding, feeding difficulty and vision 
impairment. In vascular malformations, seizures and glaucoma 
were the complications noted. 
 
• Complications of hemangiomas were found to be common among 
children born either preterm or low birth weight or both. 
 
• Hydrocephalus and subglottic involvement was noted in 2 cases of 
hemangioma; while 3 cases of Phakomatosis pigmentovascularis 
and 2 cases of Klippel Trenaunay were observed in patients with 
vascular malformation. 
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PROFORMA 
SI. No    :             Case No. :                                       
Name            :              Age              :  
Sex               : 
Informant     :              Address        : 
Complaints  : 
History of presenting illness: 
  Skin lesion       : 
  Site                   : 
  Age of onset     : 
  Mode of evolution    : 
  Sudden increase in size / Regression of lesion (spontaneously or     
with treatment)          
Bleeding on trauma/ Ulceration over lesion 
Pain/ Recurrent infection 
Sudden change in colour of lesion 
Difficulty in breathing/ feeding difficulty 
Hearing difficulty / Speech difficulty/ Visual disturbance  
Headache, seizures 
Haematuria, malena, haematemesis 
Gait disturbance  
Bladder disturbance 
History of past illness: 
 Bleeding diathesis 
Family history: 
 Similar lesions among family members  
Antenatal history/ Natal history: 
 Alcohol intake 
 Any intervention (chorionic villi sampling) 
 Prematurity / LBW 
 Oxygen therapy 
Developmental history: 
 Any delay in developmental mile stone 
Treatment history: 
 Medical/ Surgery/ Laser 
General Examination: 
 Build/ Appearance 
 Anemia/ Jaundice/ Cyanosis  
 Gait /Limb length/ Limb girth 
 Cardiac/ Respiratory status 
  
Dermatological Examination  
          Site:  
 No. of lesion: single/multiple  
 No. of dermatome involved: 
 Unilateral/ Bilateral 
 Morphology: macule/papule/plaque 
 Lesion subtype: localized/ segmental/ indeterminate/ multifocal  
 Surface/ Skin changes over lesion: any ulceration, bleeding 
 Varicose veins (if any) 
Palpation: 
 Warmth  
 Consistency        
 Compressibility   
 Mucosal involvement: 
Investigation: 
 Haemogram 
  Bleeding time  
           Clotting time  
           Platelet count             
  Hb%, TC, DC, ESR 
  X-RAY chest 
 Radiological (Individualised as per requirements in each case) 
  X-RAY soft tissue of affected region 
  USG abdomen  
      Doppler 
  CT &MRI 
 Ophthalmological examination in relevant cases 
 Biopsy (in selected cases) 
 
Diagnosis   : 
 
Follow up  : 6 months  1year    1.5years  2years 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 15 
 
 
 
 
 
  
 
 
 
 
 
     Figure 16 
 
 
 
 
 
Hemangioma below right eye 
 
Hemangioma over the scalp 
 
 
 
 Hemangioma involving the chest 
 
 
Hemangioma over the abdomen 
 
Segmental hemangioma of right forearm 
  
Hemangioma involving the back 
 
 
Hemangioma of left cheek 
  
MRI showing subglottic involvement 
 
 
Hemangioma of left shoulder 
 Hemangioma of left shoulder (Regressing) 
 
 
 Hemangioma over left arm with ulceration 
 
Hemangioma of genitalia with ulceration 
 
 
 
 Mucosal involvement 
 
 
 
Hemangioma of left side of face with hydrocephalus and occlusion of eye 
  
CT scan showing Dandy Walker 
malformation  
 
 
Segmental hemangioma of face with ulceration,  
breathing and feeding difficulty 
 
 
 
Multifocal hemangioma 
 
 
 Histopathology of hemangioma showing multiple vascular spaces  
lined by  endothelial cells 
 
 
 
  
 
Hemangioma over Left leg (showing bleeding) 
 
 
After excision 
 
 
Unilateral portwine stain with involvement of both upper and lower eyelid 
 
 
Mucosal involvement 
 
 
 Bilateral portwine stain with nevus of ota of left side 
 
 
Mucosal involvement 
 
Bilateral portwine stain with congenital melanocytic naevi 
 
 
Unilateral portwine stain with sparing of upper 
eyelid
 
 Portwine stain of right side of face 
 
 
Linear epidermal naevi involving right arm and forearm 
 
 Cases of Klippel Trenaunay syndrome showing portwine stain, 
venous varicosity and limb hypertrophy   
 
  
 
Case 
no Age
Age of 
onset Gender
No of 
derm.inv Site of lesions
Mucosal  
involvement Uni/Bilateral
Trigeminal  
br. Complications CBC
Other 
Investigations Associations
1 42Y Birth F Multiple Face Yes Unilateral Max - Normal CT-N -
2 6Y Birth F Multiple Face No Unilateral Max,oph - Normal CT-N -
3 18Y Birth F Multiple Leg - - - Gait disturbance Normal Doppler,X-Ray Ven Var& LH
4 35Y Birth M Single Face No Unilateral Max - Normal - -
5 32Y Birth F Multiple Face No Unilateral Max Normal CT-N -
6 20 Y Birth M Multiple Leg - - - Gait disturbance Normal Doppler,X-Ray Ven Var& LH
7 37Y Birth M Single Face No Unilateral Max - Normal - -
8 25Y Birth M Single Face No Unilateral Oph - Normal - -
9 19Y Birth F Multiple Face Yes Bilateral Oph,Max,Man Seizures&Glaucoma Normal CT-N CMN
10 60Y Birth F Multiple Face Yes Unilateral Max Glaucoma Normal CT-N -
11 15Y Birth F Multiple Face Yes Unilateral Oph,Max,Man Seizures Normal CT-N -
12 25Y Birth M Single Face No Unilateral Max - Normal CT-N -
13 1Y Birth M Multiple Face No Unilateral Max - Normal - Linear Epi Nevi
14 20Y Birth F Multiple Face Yes Bilateral Oph,Max,Man Glaucoma Normal CT-N,MRI Nevus of ota, CMN
15 62Y Birth M Multiple Hand - - - - Normal - -
MASTER CHART - VASCULAR MALFORMATIONS 
Case no Age Age of onset Gender No of derm.inv Site of lesions Mucosal involvement Uni/Bilateral Trigeminal br. Complications CBC Other Investigations Associations
16 40Y Birth M Single - - - - Normal - -
17 20Y Birth F Single Back - - - - Normal - -
18 36Y Birth F Single Face No Unilateral Oph - Normal - -
19 45Y Birth M Multiple Face No Unilateral Max - Normal CT-N -
20 20Y Birth F Multiple Face Yes Bilateral Oph,Max,Man Seizures Normal MRI Pitu MA
MON     =  Month Fd          =  Feeding difficulty
F            =  Female Bth         = Breathing difficulty
M           = Male CMN      = Congenital melanocytic nevi
Prog       = Progressive Ven Var  = Venous Varicosity
Reg         = Regressive LH          = Limb Hypertrophy
Non-inv  = Non-involuting Pitu MA = Pituitary Microadenoma
N            = Normal Max        = Maxillary
Oph         = Ophthalmic Man       = Mandibular                                                      
Indeter     =  Indeterminate
MASTER CHART - VASCULAR MAL FORMATIONS 
Case no. Age
Age of 
Onset Gender
Family 
History
Term/    
Pre-term
Birth 
weight
No. of 
lesions
Lesion 
subtype
Distribution of 
lesions Course Complication
Mucosal 
inv
CB
C Other investigations Associations
1 9MON Birth F No Term 2.8 Kg Single Localised Face Reg Nil No N MRI-Normal -
2 8MON 1MON F No Term 3 Kg Single Localised Back Prog Nil No N - -
3 3MON Birth F No Term 2.9 Kg Single Localised Back Prog Nil No N - -
4 1Y Birth F No Term 2.6 Kg Single Localised Chest Reg Nil No N - -
5 2Y Birth F No Term 3 Kg Single Localised Face Non-inv Nil No N CT-Normal -
6 6Y 3MON F Yes Term 3.25 Kg Multiple Indeter Leg Non-inv Bleeding No N X-RAY-N/Biopsy -
7 4Y 2MON M No 35 Weeks 1.8 Kg Single Localised Leg Non-inv Nil No N X-RAY-N -
8 2MON Birth F No Term 2.75 Kg Single Localised Face Non-inv Nil No N - -
9 2MON Birth F No Term 2.6 Kg Single Segmental Hand Prog Nil No N - -
10 4MON Birth F No Term 3.3 Kg Single Localised Scalp Non-inv Nil No N CT-Normal -
11 5MON Birth F No Term 2.9 Kg Single Indeter Hand Prog Nil No N - -
12 1MON Birth M No Term 2.75 Kg Single Localised Back Prog Nil No N - -
13 7Y Birth F No Term 3 Kg Single Segmental Face Reg Nil Yes N CT-Normal -
14 4MON Birth M No 31 Weeks 1.3 Kg Single Segmental Face Non-inv Fd/Bth Yes N MRI-Subglottic inv Subglottic inv
15 3MON Birth F No Term 2.8 Kg Single Localised Hand Non-inv Nil No N - -
MASTER CHART - HEMANGIOMAS
Case no. Age
Age of 
Onset Gender
Family 
History
Term/    
Pre-term
Birth 
weight
No. of 
lesions
Lesion 
subtype
Distribution of 
lesions Course Complication
Mucosal 
inv
CB
C Other investigations Associations
16 5MON Birth F No Term 3.2 Kg Single Localised Scalp Non-inv Nil No N - -
17 15D Birth F No Term 2.7 Kg Multiple Indeter Back Prog Nil No N - -
18 1.2Y 1MON F No Term 3.1 Kg Single Localised Face Non-inv Nil No N - -
19 1.8Y 1MON M No Term 2.6 Kg Single Localised Scalp Non-inv Nil No N - -
20 1.5Y Birth F No 34 Weeks 2.25 Kg Single Localised Scalp Non-inv Ulceration No N - -
21 2Y Birth F No Term 3 Kg Single Localised Hand Non-inv Ulceration No N X-RAY-N/Biopsy -
22 1MON Birth M Yes 35 weeks 2.6 Kg Single Segmental P Prog Vision No N CT-Dandy Walker/Echo Hydrocephalus
23 1.5Y 1MON F No Term 3.1 Kg Single Localised Genital Non-inv Ulceration Yes N - -
24 3Y Birth M No 34 weeks 2 .25Kg Single Indeter Hand Non-inv Bleeding No N Biopsy -
25 4Y Birth M No Term 2.9 Kg Single Localised Hand Reg Nil No N - -
26 2MON Birth F No 32 Weeks 2 Kg Multiple Segmental Face Prog Fd/Bth/Ulceration Yes N CT-Normal -
27 4MON Birth M No Term 3.2 Kg Single Localised Chest Prog Nil No N - -
28 1.5Y Birth F No 36 Weeks 2.75 Kg Single Localised Abdomen Non-inv Ulceration No N - -
29 2Y Birth F Yes Term 2.8 Kg Single Localised Hand Non-inv Nil No N - -
30 2MON Birth F No Term 2.6 Kg Multiple Multifocal Multiple Prog Nil No N USG abdomen-N -
MASTER CHART - HEMANGIOMAS
Case no. Age
Age of 
Onset Gender
Family 
History
Term/    
Pre-term
Birth 
weight
No. of 
lesions
Lesion 
subtype
Distribution of 
lesions Course Complication
Mucosal 
inv
CB
C Other investigations Associations
31 5Y Birth F No Term 3.1 Kg Single Localised Abdomen Non-inv Nil No N - -
32 1MON Birth F No Term 2.75 Kg Single Indeter Abdomen Non-inv Ulceration No N - -
33 5MON Birth F No Term 3 Kg Single Localised Scalp Non-inv Nil No N - -
34 3MON Birth F Yes Term 3 Kg Single Localised Face Prog Nil No N - -
35 2MON Birth F No Term 2.7 Kg Single Localised Face Non-inv Nil No N - -
36 1.4Y Birth F No Term 3.25 Kg Single Indeter Scalp Non-inv Bleeding No N - -
MASTER CHART - HEMANGIOMAS
